MVA-BN smallpox vaccine: all 31 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for MpoxCompletedNCT05740982Phase 2Results posted
- Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRCCompletedNCT05734508Phase 4Results posted
- Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox VaccineCompletedNCT05512949Phase 2Results posted
- Special Access Program IMVAMUNE®CompletedNCT03472014Phase 4Results posted
- Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV InfectionCompletedNCT02038881Phase 2Results posted
- A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®CompletedNCT01913353Phase 3Results posted
- Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®CompletedNCT01827371Phase 2Results posted
- A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve SubjectsCompletedNCT01144637Phase 3Results posted
- Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered IntradermallyCompletedNCT00914732Phase 2Results posted
- High Dose IMVAMUNE® in Vaccinia-Naive IndividualsCompletedNCT00879762Phase 2Results posted
- A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced SubjectsCompletedNCT00857493Phase 2Results posted
- An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 VaccineesCompletedNCT00686582Phase 2Results posted
- MVA Post-Event: Administration Timing and Boost StudyCompletedNCT00437021Phase 1/2Results posted
- A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic DermatitisCompletedNCT00316602Phase 2Results posted
- Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected PatientsCompletedNCT00316589Phase 2Results posted
- A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy SubjectsCompletedNCT00316524Phase 2Results posted
- ACAM 3000 MVA at Harvard Medical SchoolCompletedNCT00133575Phase 1/2Results posted
- Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsActive, not recruitingNCT07199569Phase 2
- Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus InfectionsActive, not recruitingNCT06549530Phase 2
- Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCTActive, not recruitingNCT05745987Phase 4
- Imvamune Vaccine for the Treatment of Non-melanoma Skin CancerTerminatedNCT04410874Phase 1/2
- A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy ParticipantsCompletedNCT03953196Early Phase 1
- JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the CongoCompletedNCT02977715Phase 3
- Safety Study of an Additional MVA Vaccine in Volunteers Who Received 3 DNA Vaccines Followed by 2 MVA VaccinesCompletedNCT01461447Phase 1/2
- Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) SubjectsCompletedNCT00565929Phase 1
- Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox VaccineCompletedNCT00466245Phase 2
- Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.CompletedNCT00189956Phase 2
- Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy SubjectsCompletedNCT00189943Phase 1
- Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic DisordersCompletedNCT00189917Phase 1
- Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected PatientsCompletedNCT00189904Phase 1/2
- Combination Study With MVA BN and DryvaxCompletedNCT00082446Phase 1